AskBio Receives FDA Regenerative Medicine Advanced Therapy Designation for Parkinson’s
AskBio, a Bayer AG subsidiary, announced that its investigational gene therapy AB-1005 for Parkinson’s disease received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. This designation was based on promising Phase Ib trial data, showing a favorable safety profile and positive trends in clinical outcomes. The RMAT designation aims to expedite the development of […]
Stem Cell and Gene Therapies for Parkinson’s: Revolutionary Advances with Dr. Amber Van Laar
In a recent webinar, Dr. Amber Van Laar, a movement disorder specialist and neurologist, provided a deep dive into the evolving landscape of stem cell and gene therapies for Parkinson’s disease. As the Senior Vice President of Global Clinical Development at AskBio, Dr. Van Laar discussed innovative cell-based therapies and the potential for gene therapy […]
iRegene Receives IND Approval from U.S. FDA to Start Clinical Trial for Parkinson’s Disease
iRegene Therapeutics has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting Investigational New Drug (IND) approval for their innovative cell therapy, NouvNeu001, aimed at treating Parkinson’s disease. This approval marks a pivotal step forward in the fight against this debilitating neurodegenerative disorder. A New Hope for Parkinson’s Patients Parkinson’s disease, characterized by the loss of dopaminergic neurons, […]
Aspen Neuroscience Secures CIRM Grant for Groundbreaking Parkinson’s Disease Stem Cell Therapy
In a significant stride towards combating Parkinson’s disease, Aspen Neuroscience has been awarded a prestigious CLIN2 grant by the California Institute for Regenerative Medicine (CIRM). This milestone funding will accelerate the development of their innovative stem cell therapy, ANPD001. Aspen Neuroscience’s proprietary approach leverages cutting-edge induced pluripotent stem cells (iPSCs) to create personalized therapies aimed […]
Revolutionizing Parkinson’s Disease Treatment: TreeFrog Therapeutics’ Leap Forward
In the ever-evolving field of regenerative medicine, a significant milestone is on the horizon, courtesy of TreeFrog Therapeutics. At the 23rd Congress of the Japanese Society for Regenerative Medicine (JSRM) in Niigata, Japan, a presentation by Maxime Feyeux, the Chief Scientific Officer and Co-founder of TreeFrog, has sparked excitement and hope. TreeFrog Therapeutics, a frontrunner […]
Aspen Neuroscience Cofounder Dr. Andrés Bratt-Leal Receives 2023 Biocom California Life Science Catalyst Award
Dr. Andrés Bratt-Leal, co-founder and Senior Vice President of Research and Development at Aspen Neuroscience, has been honored with the prestigious 2023 Biocom California Life Science Catalyst Award. This accolade, presented by Biocom California, recognizes the most inspiring and driven young minds in the California life sciences industry who are making significant contributions to human […]
Regenerative Medicine: Induced Pluripotent Stem Cells (iPSCs) Therapy in Neurological Disorder Treatment
In recent years, the scientific community has been abuzz with the potential of induced pluripotent stem cells (iPSCs) for treating a myriad of diseases, especially neurological disorders. The allure of iPSCs lies in their ability to morph into any cell type in the human body, a characteristic termed as pluripotency. This remarkable trait is achieved […]
FDA Grants Fast Track Designation to ANPD001 for Parkinson’s Disease Treatment
Aspen Neuroscience, a clinical development-stage company, recently announced a significant milestone in the fight against Parkinson’s disease (PD). The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ANPD001, an autologous (personalized) investigational cell therapy designed to treat Parkinson’s disease by replacing lost dopamine neurons. This designation aims to accelerate the development […]
BlueRock’s Phase I Study with Bemdaneprocel in Parkinson’s Disease Patients Achieves Main Goal
BlueRock Therapeutics, in collaboration with Bayer AG, recently announced the successful results of their Phase I clinical trial for bemdaneprocel (BRT-DA01), an innovative cellular therapy derived from stem cells, aimed at treating Parkinson’s disease. The findings were presented at the International Congress of Parkinson’s Disease and Movement Disorders in Copenhagen, Denmark. Key Highlights: Dr. Claire […]
Rune Labs and Aspen Neuroscience Collaborate on Parkinson’s Disease Study
Rune Labs, a leading precision neurology software and data platform company, has joined forces with Aspen Neuroscience Inc., a prominent autologous cell therapy biotechnology firm. The collaboration aims to leverage Rune Labs’ StriveStudy clinical development platform, enabling Aspen to gather real-time, longitudinal patient data remotely. The primary objective of this partnership is to utilize the […]